3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
4
Gastrointestinal
1
Conditions
Carcinoma, Hepatocellular
63
Colorectal Neoplasms
30
Biliary Tract Neoplasms
29
Cholangiocarcinoma
27
Pancreatic Neoplasms
26
Liver Neoplasms
18
Stomach Neoplasms
13
Esophageal Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Breast Neoplasms
10
Gallbladder Neoplasms
9
Adenocarcinoma Of Esophagus
9
Neoplasm Metastasis
8
Esophageal Squamous Cell Carcinoma
8
Ovarian Neoplasms
7
Melanoma
7
Squamous Cell Carcinoma of Head and Neck
6
Small Cell Lung Carcinoma
6
Carcinoma, Renal Cell
6
Carcinoma
6
Bile Duct Neoplasms
6
Triple Negative Breast Neoplasms
5
Rectal Neoplasms
5
Prostatic Neoplasms
5
Colonic Neoplasms
5
Uterine Cervical Neoplasms
4
Lung Neoplasms
4
Diabetes Mellitus, Insulin-Dependent, 12
4
Adenocarcinoma
4
Neoplasms
3
Interventions
Irinotecan
4
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
napabucasin
3
Cyclophosphamide
3
Bevacizumab
3
Albumin-Bound Paclitaxel
3
selpercatinib
2
pembrolizumab
2
cobimetinib
2
Sunitinib
2
Sorafenib
2
Pemetrexed
2
Paclitaxel
2
Leucovorin
2
Fluorouracil
2
Drug Therapy
2
Chemoradiotherapy
2
Cetuximab
2
Aspirin
2
Ascorbic Acid
2
trametinib
1
repotrectinib
1
pralsetinib
1
osimertinib
1
lutetium Lu 177 dotatate
1
linifanib
1
guadecitabine
1
golotimod
1
genexol-PM
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
durvalumab
×
Gastrointestinal
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled